title: Practical considerations in ovarian cancer chemotherapy.
abstract: Epithelial ovarian cancer remains the most lethal gynecologic malignancy despite advances in treatment. The standard management generally involves a combination of surgical tumor debulking and chemotherapy. Over the decades, chemotherapy for ovarian cancer has evolved and currently involves a combination of intravenous platinum and taxane chemotherapy. Over the past decade, three randomized phase III trials have been reported, and all have demonstrated a significant survival advantage for intraperitoneal compared with intravenous chemotherapy. However, there are potential barriers and controversies related to the administration of intraperitoneal chemotherapy in ovarian cancer patients. In this review, we discuss the evolution and current management considerations of chemotherapy for the treatment of epithelial ovarian cancer.
authors.affiliation: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd, Duarte, CA 91010, USA.
authors.forename: Mihaela
authors.initials: M
authors.lastname: Cristea
authors.forename: Ernest
authors.initials: E
authors.lastname: Han
authors.forename: Lennie
authors.initials: L
authors.lastname: Salmon
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Morgan